Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Gastrointestinal motility pathways" is not a single molecule, receptor, enzyme, transporter, or canonical therapeutic target. Instead, it refers to a complex network of physiological processes and signaling cascades that regulate the coordinated contraction and relaxation of smooth muscle throughout the gastrointestinal tract. These processes are essential for moving food through the digestive system via peristalsis and segmental contractions. The regulation of GI motility involves multiple cell types—including enteric neurons, interstitial cells of Cajal ("pacemaker" cells), smooth muscle cells, immune cells such as macrophages—and numerous signaling molecules. Key molecular targets within these pathways include: • **Motilin receptor**—targeted by agonists like mitemcinal to stimulate peristalsis in certain contexts[1][4][5]. • **Guanylate cyclase-C receptor**—targeted by plecanatide and linaclotide to increase intestinal fluid secretion and promote movement; common side effect is diarrhea[1]. • **5-hydroxytryptamine 4 (5‑HT₄) receptor**—agonists like prucalopride enhance gastric emptying in gastroparesis patients[2]. • **Mitogen‑activated protein kinase (MAPK) signaling components**—including ERK1/2 and p38MAPK subfamilies implicated as potential therapeutic targets due to their role in modulating contractile responses in normal/inflamed intestinal smooth muscle[6][7][10]. • **Ghrelin receptor**, which also regulates GI function alongside appetite control. • Immune mediators such as complement component C1q produced by enteric macrophages have been shown to influence neuronal activity controlling gut motility.[3] Because "gastrointestinal motility pathways" encompasses many distinct molecules rather than one defined entity, it should not be considered a canonical drug target itself but rather an umbrella term describing several possible therapeutic entry points. For structured data purposes you should extract information about individual receptors/proteins involved in this process instead. If you need details about any specific molecule/receptor from this pathway—for example "motilin receptor," "guanylate cyclase-C receptor," "5‑HT₄ receptor," etc.—please specify so that precise structured information can be provided.
Not applicable as it refers to a complex network rather than a single target; mechanisms vary depending on the specific molecular target within these pathways.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal motility pathways.